its one-dose coronavirus vaccine, putting the company on track to potentially begin shipping it by early March.
The agency has scheduled a meeting with its outside advisory panel, which will vote on whether the F.D.A. should authorize the vaccine on Feb. 26, according to people familiar with the planning.
That leaves regulators about three weeks to pore over a large and complex application that includes clinical and manufacturing data. A decision on whether to authorize the vaccine could come within days of that meeting.
A similar timeline was used for the review of two-dose vaccines made by Pfizer-BioNTech and Moderna, which were authorized by the F.D.A. in December.
Dr. Paul Stoffels, the company’s chief scientific officer, said in a statement that the application was a “pivotal step toward reducing the burden of disease for
Posts from the same category:
- None Found